Provided by Tiger Trade Technology Pte. Ltd.

OCUMENSION-B

6.960
+0.1902.81%
Volume:674.00K
Turnover:4.64M
Market Cap:5.67B
PE:-17.74
High:6.980
Open:6.890
Low:6.730
Close:6.770
52wk High:12.230
52wk Low:3.910
Shares:815.00M
HK Float Shares:815.00M
Volume Ratio:1.00
T/O Rate:0.08%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.392
ROE:-7.76%
ROA:-5.07%
PB:1.37
PE(LYR):-17.74
PS:9.19

Loading ...

ASCLETIS-B (01672): Positive Topline Results from 13-Week Phase II Study of ASC30 for Obesity Treatment

Stock News
·
Dec 08, 2025

Zhaoke Ophthalmology-B (06622) to Collaborate with Tansheng Pharma in Taiwan for Clinical Introduction and Future Commercialization of BRIMOCHOL™ PF

Stock News
·
Dec 08, 2025

ASCLETIS-B (01672) Surges Over 4% as New Drug Denifanstat Tablet's Marketing Application Accepted

Stock News
·
Dec 08, 2025

Highlight Pharmaceutical Files IPO Application with Hong Kong Stock Exchange

Deep News
·
Dec 04, 2025

ASCLETIS-B (01672) Repurchases 1.62 Million Shares for HK$20.94 Million on December 4

Stock News
·
Dec 04, 2025

ASCLETIS-B (01672) Repurchased 1.306 Million Shares for HK$15.9275 Million on December 3

Stock News
·
Dec 03, 2025

Nikkei 225 Drops Below 50,000 Points, Dragged Down by Electronics and Pharma Stocks

Deep News
·
Dec 01, 2025

ASCLETIS-B (01672) Selects Its First Oral GLP-1R/GIPR/GCGR Triple-Target Agonist Peptide ASC37 for Clinical Development

Stock News
·
Nov 30, 2025

BAIYUNSHAN PH (00874): Guanghua Pharmaceutical Signs Land Reserve Compensation Agreement with Tonghe Subdistrict Office

Stock News
·
Nov 27, 2025

Shandong Boan Biotechnology Wins China Approval for Boyoujing Aflibercept Injection

Reuters
·
Nov 26, 2025

Ocumension Therapeutics (1477) and Shandong Boan Biotechnology (6955) Obtain Chinese Approval for EYLEA® Biosimilar OT-702

Bulletin Express
·
Nov 26, 2025

OCUMENSION-B (01477): OT-702 Approved for Launch in China

Stock News
·
Nov 26, 2025

Ocumension Therapeutics Receives NMPA Approval to Market OT-702 in China

Reuters
·
Nov 26, 2025

Ocumension Therapeutics - Ot-702 Approved for Marketing by Nmpa in China

THOMSON REUTERS
·
Nov 26, 2025

From "Weight Loss Miracle Drug" to Cancer Treatments: U.S. Medicare Price Negotiations Slash Spending by 36%

Stock News
·
Nov 26, 2025

Mingyu Pharma Submits IPO Application to HKEX: Persistent Net Losses Since Inception, No Revenue from Commercial Product Sales

Deep News
·
Nov 26, 2025

HSBC Initiates Coverage on Regeneron Pharmaceuticals (REGN.US) with "Buy" Rating, Bullish on Eylea HD Growth and Oncology Pipeline Catalysts

Stock News
·
Nov 25, 2025

HK Stock Movement | ASCLETIS-B (01672) Rises Over 6% as Pharma Firms Actively Develop Ultra-Long-Acting Therapies; Company Boasts ULAP Technology Platform

Stock News
·
Nov 25, 2025

New Stock Update | Mingyu Pharma Files for Hong Kong Main Board Listing

Stock News
·
Nov 24, 2025

Novartis AG (NVS.US) Raises Peak Sales Forecasts for Two Key Cancer Drugs, Projects 5%-6% Annual Revenue Growth Through 2030

Stock News
·
Nov 20, 2025